Securian Asset Management Inc Trims Stake in Hologic, Inc. (HOLX)

Share on StockTwits

Securian Asset Management Inc decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,574 shares of the medical equipment provider’s stock after selling 303 shares during the period. Securian Asset Management Inc’s holdings in Hologic were worth $1,133,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the company. Vanguard Group Inc boosted its holdings in shares of Hologic by 1.1% in the third quarter. Vanguard Group Inc now owns 28,259,273 shares of the medical equipment provider’s stock worth $1,158,065,000 after buying an additional 303,902 shares during the period. Capital World Investors boosted its holdings in shares of Hologic by 2.5% in the third quarter. Capital World Investors now owns 27,808,896 shares of the medical equipment provider’s stock worth $1,139,609,000 after buying an additional 671,524 shares during the period. BlackRock Inc. boosted its holdings in shares of Hologic by 0.9% in the third quarter. BlackRock Inc. now owns 18,773,720 shares of the medical equipment provider’s stock worth $769,349,000 after buying an additional 164,937 shares during the period. FMR LLC boosted its holdings in shares of Hologic by 6.4% in the third quarter. FMR LLC now owns 2,438,184 shares of the medical equipment provider’s stock worth $99,916,000 after buying an additional 146,726 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Hologic by 135.9% in the third quarter. The Manufacturers Life Insurance Company now owns 1,958,778 shares of the medical equipment provider’s stock worth $80,270,000 after buying an additional 1,128,328 shares during the period. Institutional investors own 90.43% of the company’s stock.

In other news, Director Christiana Stamoulis sold 13,257 shares of Hologic stock in a transaction that occurred on Wednesday, November 28th. The shares were sold at an average price of $44.50, for a total value of $589,936.50. Following the transaction, the director now owns 48,296 shares of the company’s stock, valued at $2,149,172. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Benjamin Jordan Cohn sold 10,000 shares of Hologic stock in a transaction that occurred on Friday, November 30th. The shares were sold at an average price of $44.49, for a total transaction of $444,900.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 34,497 shares of company stock worth $1,507,865. Insiders own 0.90% of the company’s stock.

Several research analysts have commented on the stock. BidaskClub cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Monday, February 4th. Zacks Investment Research upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $49.00 target price for the company in a report on Monday, February 4th. BTIG Research reiterated a “buy” rating and issued a $50.00 target price on shares of Hologic in a report on Thursday, January 31st. Piper Jaffray Companies raised their price target on shares of Hologic to $49.00 and gave the stock an “overweight” rating in a report on Thursday, January 31st. Finally, Needham & Company LLC restated a “buy” rating and set a $50.00 price target (up from $48.00) on shares of Hologic in a report on Thursday, January 31st. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $44.27.

Shares of HOLX opened at $43.79 on Tuesday. The company has a market cap of $12.70 billion, a P/E ratio of 19.64, a price-to-earnings-growth ratio of 2.05 and a beta of 0.73. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.91 and a current ratio of 1.30. Hologic, Inc. has a twelve month low of $35.10 and a twelve month high of $45.45.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, January 30th. The medical equipment provider reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.01. The firm had revenue of $830.70 million for the quarter, compared to analyst estimates of $823.22 million. Hologic had a negative net margin of 12.88% and a positive return on equity of 25.59%. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.55 earnings per share. Analysts predict that Hologic, Inc. will post 2.41 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Securian Asset Management Inc Trims Stake in Hologic, Inc. (HOLX)” was originally posted by Highlight Press and is the sole property of of Highlight Press. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://highlightpress.com/2019/02/12/securian-asset-management-inc-trims-stake-in-hologic-inc-holx.html.

Hologic Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Article: Marijuana Stocks Future Looks Bright

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply